Lessons from the SURTAVI trial - ACC.17


International in scope, demonstrating non-inferiority as a goal, this trial uses an early iteration of the CoreValve and the new Evolut-R bioprosthesis. Join M. Gilard as she captures the key message of SURTAVI, the second trial to compare TAVI to surgery in intermediate risk patients. Learn what was the observed rate of mortality, stroke, paravalvular leak or pacemaker use and understand why this can have an impact on future guidelines for patients eligible for TAVI. Learn more today…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).